Building an investable
IP portfolio

Is your IP portfolio ready for investment, licensing, or acquisition?‍

For biotech and pharmaceutical companies, intellectual property is often the single most valuable business asset. A well-designed IP strategy can increase company valuation, strengthen fundraising efforts, support licensing discussions, and improve acquisition prospects.

In this whitepaper, EIP's Stratiphy® team explores how life sciences innovators can build an investable IP portfolio that balances scientific progress, commercial objectives, and investor expectations. Whether you're preparing for seed funding, scaling towards clinical trials, or positioning for acquisition, this whitepaper provides actionable insights on developing an IP strategy that supports long-term growth and commercial success.
‍
Download Building an Investable IP Portfolio in Biotech and Pharma to start building a more investable portfolio today.

• Develop a cost-effective patent strategy
  Learn how to prioritise patent protection, align IP decisions with business goals, and manage costs without compromising value.
• Get patent filing timing right
  Discover the factors that influence filing strategy and why timing can significantly impact investment attractiveness and future patent value.
• Protect the right assets in the right markets
  Understand what to protect, where to file, and how to build a patent portfolio that supports commercial objectives
• Manage freedom-to-Operate risks
  Explore best practices for identifying and addressing third-party patent risks throughout the R&D and commercialisation lifecycle.
• Structure collaborations for growth
  Learn how partnership agreements, licensing arrangements, and joint development projects can affect company valuation and investment readiness.
• Maximise patent term extensions
  Understand how Supplementary Protection Certificates (SPCs) and patent term extensions can add valuable years of protection to pharmaceutical innovations.

The goal is to build a defendable, investor-ready portfolio that grows in step with scientific and commercial milestones on the route to market, investment or acquisition.